Diabetes and Pediatric and Dialysis The objective of this study is to analyze the incidence of diabetes among pediatric patients, with dialysis, by way of analysis of outcomes one year following diagnosis.

Initiatives concerned with investigating pediatric diabetes have previously been associated with varying outcomes. What factors are linked with diabetes, pediatric patients, and dialysis with regards to Glycated hemoglobin (HbA1c) determinants? This forms the groundwork of the paper.

Protection of Human Participants iii. Data collection

Data management and Study Design

Control of blood glucose, as shown by levels of hemoglobin A1c (HbA1c), serves as one of the clearest forecasters of lasting complications in adults as well as children suffering from type 1 diabetes mellitus (T1D). This includes diabetic nephropathy, proliferative retinopathy, age-adjusted mortality, and cardiovascular disease rates.

Hemoglobin A1c is the form of hemoglobin in the blood (red blood cells) that develops when elevated sugars are present. The sugar binds to the hemoglobin, which normally functions to deliver oxygen throughout the body, and leads to impaired oxygen-binding and release. Because HbA1c is directly correlated with blood glucose levels, physicians can use the HbA1c measurement to determine whether a given patients 'glucose control' is adequate or inadequate. Poor control of glucose during the initial years of type 1 diabetes (T1D) in children is expected to cause development of retinopathy and micro-albuminuria in adulthood; this is because of the impaired oxygen delivery resultant. Though reports exist on factors concerning HbA1c in individuals having established T1D, no published research can be found on the relationship of HbA1c in terms of socioeconomic and diabetes-specific factors, during the disease's early stages, in a sample representing children treated in United States (U.S.) pediatric diabetes centers (Redondoa, Connor & Ruedyb, 2014).

Significance of the study in Nursing Practice

The research of the Pediatric Diabetes Consortium (PDC) Type 1 diabetes New Onset (NeOn) aims to improve care provided to children having diabetes by sharing the best practices. This huge, ethnically and geographically diverse group...

This work is significant to the field of nursing because it facilitates monitoring of the condition, as well as providing insightful information on new directions that may be useful in patient care.
Protection of Human Participants

Protection of Personal Information

In obtaining data on the participants for the purpose of the study, all sensitive details regarding the participants was kept private. The protocol that was followed was consistent with standards established by the Institutional Review Board (IRB). General information centered on gender and age; no specific details were disclosed.

Source of consent and voluntary Participation

The participants' consent was obtained, as is the IRB's requirement. All participants took part voluntarily in the study, so long as the age requirement of less than 19 years was met. The large number of participating individuals and their responsiveness demonstrated that a great willingness was present on the people's part to voluntarily contribute to the process.

Data Collection

Variables

Key variables were defined and identified clearly. Both dependent and independent variables were included. In case of the independent variable, age, all participants had to strictly be aged below 19 years and also have been Pediatric Diabetes Consortium (PDC) participants for at least three months. The dependent variable, body weight, was governed highly by age and gender (independent variable). Weight and height independently contributed to the determination of Body Mass Index (BMI) as a dependent variable. A one-year-duration was established for the analysis.

Method of Data Collection

Data on clinical characteristics, demographics, and socioeconomic status were obtained from interviews with patients/parents, and medical records.

Rationale used in Data Collection

Diabetes ketoacidosis (DKA), as a standard rationale, was defined as per the criteria of the Diabetes Control and Complications Trial (DCCT). This measurement is bicarbonate (HCO3-1) levels at